| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SPRY2 |
| Uniprot No | O43597 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-315aa |
| 氨基酸序列 | MEARAQSGNGSQPLLQTPRDGGRQRGEPDPRDALTQQVHVLSLDQIRAIRNTNEYTEGPTVVPRPGLKPAPRPSTQHKHERLHGLPEHRQPPRLQHSQVHSSARAPLSRSISTVSSGSRSSTRTSTSSSSSEQRLLGSSFSSGPVADGIIRVQPKSELKPGELKPLSKEDLGLHAYRCEDCGKCKCKECTYPRPLPSDWICDKQCLCSAQNVIDYGTCVCCVKGLFYHCSNDDEDNCADNPCSCSQSHCCTRWSAMGVMSLFLPCLWCYLPAKGCLKLCQGCYDRVNRPGCRCKNSNTVCCKVPTVPPRNFEKPT |
| 预测分子量 | 42.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SPRY2重组蛋白的3篇代表性文献概览(注：以下内容基于领域知识模拟，具体文献可能需要通过学术数据库验证)：
---
1. **文献名称**: "SPRY2 inhibits ERK activation by binding to C-Raf and modulating its activity"
**作者**: Sasaki, A., et al.
**摘要**: 本研究利用重组SPRY2蛋白进行体外结合实验，发现其直接与C-Raf激酶相互作用，抑制Ras/MAPK信号通路的激活。重组SPRY2在HEK293细胞中过表达显著降低EGF诱导的ERK磷酸化，提示其作为MAPK通路负调控因子的作用。
2. **文献名称**: "SPRY2 suppresses tumor cell migration through regulation of receptor tyrosine kinase signaling"
**作者**: Edwin, F., et al.
**摘要**: 通过表达重组SPRY2蛋白，研究发现其抑制多种癌细胞(如乳腺癌MCF-7)的迁移和侵袭能力。机制上，SPRY2通过结合FGFR1并干扰其下游PI3K/AKT信号传导，为SPRY2的肿瘤抑制功能提供了实验依据。
3. **文献名称**: "Structural insights into the SPRY domain-mediated interactions of SPRY2"
**作者**: Daigo, Y., & Nakamura, Y.
**摘要**: 本研究解析了重组SPRY2蛋白的晶体结构，揭示其SPRY结构域的关键氨基酸残基参与结合TPR motif蛋白。结构数据结合突变分析表明，SPRY2通过特定结构域介导与伴侣蛋白的相互作用，影响细胞定位和功能。
---
**提示**：如需具体文献，建议在PubMed或Google Scholar中检索关键词“SPRY2 recombinant protein”或“SPRY2 structure/function”，并筛选近十年高被引论文以获取最新进展。
**Background of SPRY2 Recombinant Protein**
SPRY2 (SPRY domain-containing protein 2) is a member of the SPRY protein family, characterized by a conserved SPRY domain involved in protein-protein interactions and signaling regulation. Encoded by the *SPRY2* gene in humans, this protein plays a dual role in cellular processes, acting as both a tumor suppressor and a modulator of receptor tyrosine kinase (RTK) pathways, such as MAPK/ERK and PI3K/AKT. SPRY2 is known to inhibit cell proliferation, migration, and survival in various cancers by antagonizing growth factor signaling. Its dysregulation, through mechanisms like promoter hypermethylation or miRNA targeting, is linked to tumor progression in breast, lung, liver, and prostate cancers.
Recombinant SPRY2 protein is artificially produced using expression systems (e.g., *E. coli*, mammalian cells) to study its biological functions. Purified via affinity chromatography, it retains the native structure and activity required for experimental applications. Researchers utilize SPRY2 recombinant protein to investigate its interactions with signaling molecules (e.g., Raf-1. Cbl), dissect its tumor-suppressive mechanisms, and explore therapeutic strategies. Additionally, it serves as a tool for structural studies, antibody development, and high-throughput drug screening.
In translational research, SPRY2 recombinant protein aids in identifying biomarkers and validating targets for cancer therapies. Its role in fibrosis, angiogenesis, and metabolic disorders is also under exploration, highlighting its broad relevance in human diseases.
×
